|“This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 767419”|
What is it useful for?
ColoFast is intended for the quantitative detection of colorectal neoplasia in human plasma samples. A positive result may indicate the presence of colorectal cancer or advanced adenomas and should be followed by diagnostic colonoscopy. ColoFast is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Which patients should use ColoFast?
ColoFast is indicated to screen adults of either sex, 50 years or older, who are at average-risk for CRC. ColoFast is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Benefits for patients of a blood test
ColoFast could significantly contribute to improve the compliance for colon cancer screening since it is fast, easy, and non-invasive. Therefore, as a blood test, it may appeal to individuals who have shunned other screening approaches and it may help reach the goal of The American Cancer Society and the Centers for Disease Control of increasing colon cancer screening rate to 80% by the year 2018.
The United States Preventive Services Task Force (USPSTF) recommends seven different screening strategies, but does not specify a preference, stating that any test that brings more people into screening is better than no screening. ColoFast provides an attractive alternative for the CRC target population to potentially increase screening.
Better diagnostic performance for premalignant lesions
ColoFast has higher sensitivity for the detection of advanced adenomas than any other test on the market (including FIT, Epi procolon® and Cologuard®). Consequently, it could prevent more cancer cases and therefore reduce cancer-related mortality, the first priority for Health Authorities worldwide.